Market Overview

UPDATE: Goldman Sachs Upgrades Amgen to CL-Buy on Favorable Catalysts, Upside Potential

Related AMGN
Biotech Enters Reporting Season With Large Caps Central To Sector Performance
UPDATE: Amgen Announces Positive Phase 3 Results For AMG 416 For the Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease Receiving Hemodialysis(
Yellen Swats Down Biotech, Social Media Stocks (Fox Business)

In a report published Wednesday, Goldman Sachs analyst Terence Flynn upgraded the rating on Amgen (NASDAQ: AMGN) from Neutral to Conviction List Buy, and raised the price target from $100.00 to $130.00.

In the report, Flynn noted, “We switch to AMGN from BIIB, as we see a more favorable combination of catalysts and upside potential. AMGN is entering a period where several of its key biologic franchises are coming off patent between 4Q13 and 2H15. However, we believe this is anticipated by investors and for the most part already reflected in consensus estimates. We project that AMGN's pipeline (key readouts in 1Q14-2015) and own biosimilars (first launch in 2017) will allow it to replace the potential revenue that could be lost to competition and grow its base.”

Amgen closed on Tuesday at $104.21.

Posted-In: Goldman SachsAnalyst Color Upgrades Analyst Ratings

 

Most Popular

Related Articles (AMGN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free

Benzinga Professional